Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 3/20 | 0.52 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.52 |
| ▸ | AR | P10275 | 7/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30478001 | 0.86 | DYRK1A (0.53) | IMPDH2IMPDH1ARDYRK1AKDM4E | |
| SCHEMBL1343833 | 0.86 | DYRK1A (0.53) | IMPDH2IMPDH1ARDYRK1AKDM4E | |
| SCHEMBL29489135 | 0.85 | IMPDH2 (0.64) | IMPDH2IMPDH1ARKDM4EALDH1A1 | |
| SCHEMBL151936 | 0.85 | IMPDH2 (0.64) | IMPDH2IMPDH1ARKDM4EALDH1A1 | |
| SCHEMBL11193357 | 0.83 | IMPDH2 (0.61) | IMPDH2IMPDH1ARKDM4EALDH1A1 | |
| SCHEMBL11200010 | 0.81 | IMPDH2 (0.55) | IMPDH2IMPDH1ARKDM4EALDH1A1 | |
| SCHEMBL11228244 | 0.80 | IMPDH2 (0.59) | IMPDH2IMPDH1ARKDM4EALDH1A1 | |
| SCHEMBL16917824 | 0.78 | IMPDH2 (0.57) | IMPDH2IMPDH1ARKDM4EALDH1A1 | |
| SCHEMBL7207783 | 0.77 | RXFP1 (0.40) | IMPDH2IMPDH1KDM4EALDH1A1GAA | |
| SCHEMBL14873787 | 0.77 | RXFP1 (0.36) | IMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118955327-A | Synthesis method of 4-bromo-1-naphthalene carbonitrile | 安徽大学 | 2024-11-15 | — | — | CN | claimed |
| CN-116813834-B | Flexible stretchable organic room-temperature phosphorescent material and preparation method thereof | 南京邮电大学 | 2023-11-14 | — | — | CN | claimed |
| CN-116813834-A | Flexible stretchable organic room-temperature phosphorescent material and preparation method thereof | 南京邮电大学 | 2023-09-29 | — | — | CN | claimed |
| CN-114133387-B | Fluorescent probe with viscosity sensing property and capable of targeting multiple organelles | 郑州大学 | 2023-04-07 | — | — | CN | claimed |
| CN-114874197-A | Viscosity fluorescent probe capable of targeting various organelles | 郑州大学 | 2022-08-09 | — | — | CN | claimed |
| CN-114133387-A | Fluorescent probe with viscosity sensing property and capable of targeting multiple organelles | 郑州大学 | 2022-03-04 | — | — | CN | claimed |
| CN-112724153-A | Three lyotropic colorimetric/lyotropic fluorescent probes with dual mitochondrial/lysosomal targeting | 郑州大学 | 2021-04-30 | — | — | CN | claimed |
| CN-109734671-B | Benzimidazole derivative, preparation method and application thereof | 北京医药集团有限责任公司 | 2021-03-09 | — | — | CN | claimed |
| CN-107400090-B | Synthesis method of benzimidazole derivative | 华润赛科药业有限责任公司 | 2020-02-07 | — | — | CN | claimed |
| EP-4126835-B1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2026-02-18 | — | — | EP | disclosed |
| US-12516038-B2 | Inhibitors of antigen presentation by HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2026-01-06 | — | — | US | disclosed |
| US-20250346587-A1 | NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC DERIVATIVES AS CHECKPOINT KINASE 1 INHIBITOR AND USES THEREOF | SPEROGENIX THERAPEUTICS LTD (CN) | 2025-11-13 | — | — | US | disclosed |
| US-20250289826-A1 | PLPRO PROTEIN INHIBITOR, AND PREPARATION METHOD AND APPLICATION THEREOF | TSINGHUA UNIVERSITY (CN) | 2025-09-18 | — | — | US | disclosed |
| WO-2025135309-A1 | ORGANIC LIGHT-EMITTING COMPOUND, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME | 솔루스첨단소재 주식회사 | 2025-06-26 | — | — | WO | disclosed |
| US-20040180235-A1 | Fluorescent diketopyrrolopyrroles | CIBA SPECIALTY CHEMICALS CORP. | 2004-09-16 | — | — | US | disclosed |
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
| EP-1399514-A2 | FLUORESCENT DIKETOPYRROLOPYRROLES | Ciba SC Holding AG (CH) | 2004-03-24 | — | — | EP | disclosed |
| EP-1345930-A2 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2003002672-A2 | FLUORESCENT DIKETOPYRROLOPYRROLES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-01-09 | — | — | WO | disclosed |
| WO-2002050067-A2 | PHARMACEUTICAL HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346587-A1 | NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC DERIVATIVES AS CHECKPOINT KINASE 1 INHIBITOR AND USES THEREOF | CHEK1, CHEK2, BUB1 | IMPDH2 717/4885IMPDH1 458/4885AR 2944/4885 |
| US-20040180235-A1 | Fluorescent diketopyrrolopyrroles | TYR, QDPR, PDK1 | IMPDH2 942/4885IMPDH1 920/4885AR 3635/4885 |
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | IMPDH2 3369/4885IMPDH1 2164/4885AR 607/4885 |
| US-20250289826-A1 | PLPRO PROTEIN INHIBITOR, AND PREPARATION METHOD AND APPLICATION THEREOF | ACE, PLP2, ACE2 | IMPDH2 2418/4885IMPDH1 1940/4885AR 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.